Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anlotinib and Trastuzumab Deruxtecan
- Development stage
- Unknown
- Lead developer
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
The combination of anlotinib and trastuzumab deruxtecan is being investigated as a treatment option for various types of breast cancer, particularly HER2-positive and HER2-low breast cancer with brain metastases. This combination therapy leverages two distinct mechanisms: trastuzumab deruxtecan, an antibody-drug conjugate that targets HER2 receptors and releases a topoisomerase I inhibitor (deruxtecan/DXd) intracellularly, and anlotinib, a multi-target tyrosine kinase inhibitor. This dual approach aims to improve efficacy, especially in challenging settings like brain metastases.
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)PDGFRB (Platelet-derived growth factor receptor beta)TOP1 (DNA Topoisomerase I)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on Anlotinib and Trastuzumab Deruxtecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anlotinib and Trastuzumab Deruxtecan.